Multicenter, international, double-blind, placebo-controlled, parallel, controlled and randomized trial of a combination of low and fixed dose with antihypertensive effect (Triple Pill) as a standard treatment in patients with a history of acute ICH and levels of systolic blood pressure (SBP) defined as at least; high normal to high borderline (130 mmHg), and under minimal or no treatment for BP reduction according to current guidelines. Two-phase design. Phase 1: Determine the efficacy, tolerance, safety and adherence to a single low-dose, fixed-combination pill with an antihypertensive effect (Pill – telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mg) compared to placebo in patients with recent acute stroke (stroke) due to spontaneous intraparenchymal cerebral hemorrhage (HIP). Phase 2: Determine the effectiveness of the most intensive reduction in blood pressure (BP) provided by a strategy as a standard treatment, at the time of the first occurrence of recurrent stroke after HIP.
Further information: https://www.tridentstudy.org/